NYT piece on Altos and cell rejuvenation, the hype is strong but I'm curious
Posted by tiredmira in Research & News - 3 points, 4 comments.
NYT Magazine just dropped a long read on Altos Labs and the whole "rejuvenation" biotech wave, where they've apparently taken skin cells from 90-year-olds and made them act young again in the lab. The piece basically asks whether all this Yamanaka factor stuff is finally gonna translate into something real for humans, or if we're just chasing cellular fountain of youth vibes forever.
My honest take is that this stuff always reads way cleaner in a dish than it does in an actual person. The article leans pretty optimistic but I kept thinking about how partial reprogramming has been hyped for years and we still don't have a single approved therapy from it. Cellular age reversal in a petri dish is cool, but getting that to do anything useful without causing tumors is a whole different ball game.
I do think the funding finally showing up at this scale matters though. Anyone here following Altos or similar groups, do you actually think we'll see a real human trial with meaningful endpoints in the next five years, or is this still firmly in the "interesting but distant" bucket? 🥗
Comments
- weekendnate: The dish to person gap is real, and it's the part most of these pieces gloss over. Yamanaka factors in fibroblasts look amazing on a marker panel, then you start worrying about teratoma risk and the whole thing stalls. Altos has the money, which helps, but money doesn't fix the delivery problem. I'd be more bullish if I saw anyone publishing honest partial reprogramming work in a living mammal with functional endpoints, not just younger-looking histology. Five years feels aggressive for an appr
- tiredmira: Totally agree on the delivery piece, that's basically where every longevity company hits the same wall. The money is there but how do you even get partial reprogramming to the right cells in a living person without causing weirdness elsewhere. Yeah I'm with you on the five year thing being aggressive, a small early safety trial with decent biomarker readouts feels more realistic if they go careful with it.
- patient_codes: The delivery problem is exactly the thing nobody wants to talk about in these pieces. Like sure, you can reprogram a fibroblast in a dish, but getting those factors where they need to go in a whole living organism without triggering cancer, that's the actual hard part. I'm a pharmacologist and it still feels like we're early innings on the logistics. My bet is on combination approaches, maybe pairing something like this with better delivery vectors. That might push it out another decade but mak
- tiredmira: Yeah delivery is basically the whole bottleneck. You nailed it. I'm less optimistic on the timeline though, even a decade feels generous when you factor in the tumor risk stuff. The vector problem is what kills most of these programs quietly 😅
Community discussion - research and educational context only. Not medical advice.